Drug Trial Radar · NCT06927999
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jul 9, 2025
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- ARS Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Conditions
- Urticaria Chronic
Interventions
PlaceboDrug
Placebo solution nasal spray containing no active drug
0.5 mg epinephrineDrug
0.5 mg epinephrine per spray
1 mg epinephrineDrug
1 mg epinephrine per spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itchTime frame: 12 months
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Endeavor Health Clinical Trials Center
Glenview, Illinois · Recruiting
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio · Recruiting
Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30
Berlin, Germany · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.